Joanna C Neill

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3696987/publications.pdf

Version: 2024-02-01

71102 95266 5,794 115 41 68 citations h-index g-index papers 119 119 119 4773 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Novel antidepressant drugs: Beyond monoamine targets. CNS Spectrums, 2023, 28, 6-15.	1.2	19
2	Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology, 2022, 36, 258-272.	4.0	103
3	In memory of Professor Iain Wilkinson: cognitive and neuroimaging endophenotypes in a consanguineous schizophrenia multiplex family. Psychological Medicine, 2022, , 1-9.	4.5	1
4	The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia. Neuropharmacology, 2022, 208, 108982.	4.1	6
5	Inflammation and Brain Structure in Schizophrenia and Other Neuropsychiatric Disorders. JAMA Psychiatry, 2022, 79, 498.	11.0	99
6	Neural mechanisms underlying psilocybin's therapeutic potential – the need for preclinical in vivo electrophysiology. Journal of Psychopharmacology, 2022, 36, 781-793.	4.0	13
7	A Recessively Inherited Risk Locus on Chromosome 13q22-31 Conferring Susceptibility to Schizophrenia. Schizophrenia Bulletin, 2021, 47, 796-802.	4.3	3
8	Towards Novel Treatments for Schizophrenia: Molecular and Behavioural Signatures of the Psychotropic Agent SEP-363856. International Journal of Molecular Sciences, 2021, 22, 4119.	4.1	26
9	Standard versus reduced dose of antipsychotics for relapse prevention in multi-episode schizophrenia: a systematic review and meta-analysis of randomised controlled trials. Lancet Psychiatry,the, 2021, 8, 471-486.	7.4	36
10	Withdrawal-associated relapse is a potential source of bias – Authors' reply. Lancet Psychiatry,the, 2021, 8, 748-749.	7.4	0
11	Maternal immune activation in rodent models: A systematic review of neurodevelopmental changes in gene expression and epigenetic modulation in the offspring brain. Neuroscience and Biobehavioral Reviews, 2021, 129, 389-421.	6.1	29
12	Synaptic biomarker reduction and impaired cognition in the sub-chronic PCP mouse model for schizophrenia. Journal of Psychopharmacology, 2020, 34, 115-124.	4.0	14
13	Psychiatric Drug Discovery and Development. , 2020, , 35-68.		2
14	Aerobic exercise improves memory and prevents cognitive deficits of relevance to schizophrenia in an animal model. Journal of Psychopharmacology, 2020, 34, 695-708.	4.0	5
15	Cognitive dysfunction in diabetic rats is prevented by pyridoxamine treatment. A multidisciplinary investigation. Molecular Metabolism, 2019, 28, 107-119.	6.5	19
16	Cognitive dysfunction in major depression: From assessment to novel therapies., 2019, 202, 53-71.		41
17	Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory. Journal of Psychopharmacology, 2019, 33, 1274-1287.	4.0	12
18	T109. MODULATORY ACTIVITY OF THE NOVEL DRUG SEP-363856 ON BRAIN FUNCTION: POTENTIAL APPLICATION FOR THE TREATMENT OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2019, 45, S246-S246.	4.3	2

#	Article	IF	CITATIONS
19	Mapping the impact of exposure to maternal immune activation on juvenile Wistar rat brain macroand microstructure during early post-natal development. Brain and Neuroscience Advances, 2019, 3, 239821281988308.	3.4	3
20	Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects. Brain, Behavior, and Immunity, 2019, 75, 48-59.	4.1	66
21	Stabilized Low-n Amyloid-Î ² Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat. Journal of Alzheimer's Disease, 2018, 62, 213-226.	2.6	7
22	NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update. Neuropharmacology, 2018, 142, 41-62.	4.1	117
23	F231. GYM RATS: EXERCISE REVERSES COGNITIVE IMPAIRMENT IN THE PHENCYCLIDINE RAT MODEL OF SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S312-S312.	4.3	0
24	Restrictions on drugs with medical value: Moving beyond stalemate. Journal of Psychopharmacology, 2018, 32, 1053-1055.	4.0	5
25	T40. GPR52 AGONISTS REPRESENT A NOVEL APPROACH TO TREAT UNMET MEDICAL NEED IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S128-S128.	4.3	2
26	Partial agonism at the $\hat{l}\pm7$ nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats. European Neuropsychopharmacology, 2017, 27, 325-335.	0.7	22
27	Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation. Journal of Psychopharmacology, 2017, 31, 660-666.	4.0	14
28	Pharmacology of cognition: a panacea for neuropsychiatric disease?. British Journal of Pharmacology, 2017, 174, 3133-3135.	5.4	7
29	Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain. Epigenomics, 2016, 8, 1179-1183.	2.1	22
30	Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine. Journal of Psychopharmacology, 2016, 30, 1141-1144.	4.0	28
31	Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model. Behavioural Brain Research, 2016, 312, 93-101.	2.2	16
32	A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies. Neuroscience and Biobehavioral Reviews, 2016, 68, 979-1000.	6.1	59
33	Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. European Neuropsychopharmacology, 2016, 26, 3-14.	0.7	70
34	Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control., 2016, 158, 41-51.		34
35	Nicotinic $\hat{l}\pm7$ and $\hat{l}\pm4\hat{l}^22$ agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders. Behavioural Brain Research, 2016, 302, 73-80.	2.2	28
36	Impaired Limbic Cortico-Striatal Structure and Sustained Visual Attention in a Rodent Model of Schizophrenia. International Journal of Neuropsychopharmacology, 2015, 18, pyu010-pyu010.	2.1	28

#	Article	IF	Citations
37	Putative therapeutic targets for symptom subtypes of adult ADHD: D4 receptor agonism and COMT inhibition improve attention and response inhibition in a novel translational animal model. European Neuropsychopharmacology, 2015, 25, 454-467.	0.7	34
38	A systematic review and meta-analysis of cognitive remediation in early schizophrenia. Schizophrenia Research, 2015, 168, 213-222.	2.0	163
39	Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents. Behavioural Brain Research, 2015, 285, 176-193.	2.2	170
40	Positive effects of a novel cognitive remediation computer game (X-Cog) in first episode psychosis: a pilot study. Psychosis, 2014, 6, 215-219.	0.8	4
41	Pay attention to impulsivity: Modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats. European Neuropsychopharmacology, 2014, 24, 1371-1380.	0.7	49
42	The involvement of distraction in memory deficits induced by NMDAR antagonism: Relevance to cognitive deficits in schizophrenia. Behavioural Brain Research, 2014, 266, 188-192.	2.2	15
43	Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: A translational link to humans. European Neuropsychopharmacology, 2014, 24, 822-835.	0.7	105
44	Assessment of cognitive function across pregnancy using CANTAB: A longitudinal study. Brain and Cognition, 2014, 84, 76-84.	1.8	33
45	The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania. Expert Opinion on Drug Discovery, 2013, 8, 93-103.	5.0	23
46	First episode psychosis patients show impaired cognitive function – a study of a South Asian population in the UK. Journal of Psychopharmacology, 2013, 27, 366-373.	4.0	17
47	PNU-120596, a positive allosteric modulator of $\hat{l}\pm7$ nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats. Journal of Psychopharmacology, 2012, 26, 1265-1270.	4.0	75
48	Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. Neuropharmacology, 2012, 62, 1432-1441.	4.1	59
49	D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology, 2012, 220, 129-141.	3.1	44
50	Biological Basis of Sex Differences in Psychopharmacology. Current Topics in Behavioral Neurosciences, 2011, , .	1.7	6
51	Activation of $\hat{l}\pm7$ nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia. European Neuropsychopharmacology, 2011, 21, 333-343.	0.7	54
52	Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia. Psychopharmacology, 2011, 214, 403-413.	3.1	40
53	Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology, 2011, 214, 843-853.	3.1	36
54	Phencyclidine (PCP)-Induced Disruption in Cognitive Performance is Gender-Specific and Associated with a Reduction in Brain-Derived Neurotrophic Factor (BDNF) in Specific Regions of the Female Rat Brain. Journal of Molecular Neuroscience, 2011, 43, 337-345.	2.3	53

#	Article	IF	CITATIONS
55	The Efficacy of Sodium Channel Blockers to Prevent Phencyclidine-Induced Cognitive Dysfunction in the Rat: Potential for Novel Treatments for Schizophrenia. Journal of Pharmacology and Experimental Therapeutics, 2011, 338, 100-113.	2.5	18
56	PD168077, a D ₄ receptor agonist, reverses object recognition deficits in rats: potential role for D ₄ receptor mechanisms in improving cognitive dysfunction in schizophrenia. Journal of Psychopharmacology, 2011, 25, 792-800.	4.0	27
57	Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT6 and 5-HT2A receptor mechanisms. Psychopharmacology, 2010, 208, 23-36.	3.1	68
58	Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism., 2010, 128, 419-432.		463
59	Effects of subchronic phencyclidine on behaviour of female rats on the elevated plus maze and open field. Journal of Psychopharmacology, 2010, 24, 787-790.	4.0	16
60	Attenuation of Phencyclidine-Induced Object Recognition Deficits by the Combination of Atypical Antipsychotic Drugs and Pimavanserin (ACP 103), a 5-Hydroxytryptamine _{2A} Receptor Inverse Agonist. Journal of Pharmacology and Experimental Therapeutics, 2010, 332, 622-631.	2.5	84
61	Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. International Journal of Neuropsychopharmacology, 2010, 13, 1021-1033.	2.1	100
62	TIME-DEPENDENT CHANGES IN GAMMA OSCILLATIONS AND PARVALBUMIN IMMUNOREACTIVE CELL DENSITY IN THE CA2/3 REGION OF THE RAT HIPPOCAMPUS FOLLOWING SUB-CHRONIC PHENCYCLIDINE TREATMENT. Schizophrenia Research, 2010, 117, 486.	2.0	0
63	Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Behavioural Brain Research, 2010, 207, 144-150.	2.2	45
64	Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat. Behavioural Brain Research, 2010, 214, 240-247.	2.2	39
65	Isolation rearing impairs novel object recognition and attentional set shifting performance in female rats. Journal of Psychopharmacology, 2010, 24, 57-63.	4.0	103
66	Comparison of the efficacy of two anticonvulsants, phenytoin and valproate to improve PCP and d-amphetamine induced deficits in a reversal learning task in the rat. Frontiers in Behavioral Neuroscience, 2009, 3, 8.	2.0	8
67	Subchronic Effects of Phencyclidine on Dopamine and Serotonin Receptors: Implications for Schizophrenia. Journal of Molecular Neuroscience, 2009, 38, 227-235.	2.3	31
68	Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat. Psychopharmacology, 2009, 206, 403-414.	3.1	62
69	Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors. Psychopharmacology, 2009, 207, 119-125.	3.1	76
70	D1-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. European Neuropsychopharmacology, 2009, 19, 440-450.	0.7	63
71	Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats—A preliminary investigation. Behavioural Brain Research, 2008, 187, 489-494.	2.2	67
72	A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behavioural Brain Research, 2008, 189, 152-158.	2.2	86

#	Article	IF	Citations
73	Improvement of phencyclidine-induced social behaviour deficits in rats: Involvement of 5-HT1A receptors. Behavioural Brain Research, 2008, 191, 26-31.	2.2	77
74	Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. Journal of Psychopharmacology, 2008, 22, 182-186.	4.0	18
75	Oestradiol attenuates the cognitive deficit induced by acute phencyclidine treatment in mature female hooded-Lister rats. Journal of Psychopharmacology, 2008, 22, 918-922.	4.0	23
76	Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. Journal of Psychopharmacology, 2008, 22, 567-571.	4.0	30
77	Sub-chronic psychotomimetic phencyclidine induces deficits in reversal learning and alterations in parvalbumin-immunoreactive expression in the rat. Journal of Psychopharmacology, 2007, 21, 198-205.	4.0	193
78	Influence of gender on working and spatial memory in the novel object recognition task in the rat. Behavioural Brain Research, 2007, 177, 117-125.	2.2	202
79	Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research, 2007, 184, 31-38.	2.2	222
80	The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology, 2007, 194, 221-231.	3.1	54
81	The effect of atypical and classical antipsychotics on sub-chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research, 2006, 169, 263-273.	2.2	128
82	Investigation of the effects of lamotrigine and clozapine in improving reversal-learning impairments induced by acute phencyclidine and d-amphetamine in the rat. Psychopharmacology, 2005, 179, 336-348.	3.1	109
83	Effects of sub-chronic antipsychotic drug treatment on body weight and reproductive function in juvenile female rats. Psychopharmacology, 2005, 182, 499-507.	3.1	31
84	Investigation into the effects of the novel antipsychotic ziprasidone on weight gain and reproductive function in female rats. Behavioural Brain Research, 2005, 160, 338-343.	2.2	24
85	Effects of the Atypical Antipsychotic Olanzapine on Reproductive Function and Weight Gain in Female Rats. Journal of Psychopharmacology, 2004, 18, 149-155.	4.0	57
86	Ziprasidone suppresses olanzapine-induced increases in ingestive behaviour in the rat. European Journal of Pharmacology, 2004, 505, 253-254.	3.5	35
87	Calcium binding protein markers of GABA deficits in schizophrenia â€" post mortem studies and animal models. Neurotoxicity Research, 2004, 6, 57-61.	2.7	145
88	Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats. European Neuropsychopharmacology, 2004, 14, 385-392.	0.7	38
89	The atypical antipsychotic ziprasidone, but not haloperidol, improves phencyclidine-induced cognitive deficits in a reversal learning task in the rat. Journal of Psychopharmacology, 2003, 17, 57-66.	4.0	103
90	Correlation of Hyperforin Content of Hypericum Perforatum(St John's Wort) Extracts with Their Effects On Alcohol Drinking in C57Bl/6J Mice: A Preliminary Study. Journal of Psychopharmacology, 2003, 17, 403-408.	4.0	16

#	Article	IF	Citations
91	H1-histamine Receptor Affinity Predicts Short-term Weight Gain for Typical and Atypical Antipsychotic Drugs. Neuropsychopharmacology, 2003, 28, 2209-2209.	5.4	24
92	The atypical antipsychotic olanzapine enhances ingestive behaviour in the rat: a preliminary study. Journal of Psychopharmacology, 2002, 16, 35-37.	4.0	51
93	The Dopamine D3/D2 Receptor Agonist 7-OH-DPAT Induces Cognitive Impairment in the Marmoset. Pharmacology Biochemistry and Behavior, 1999, 63, 201-211.	2.9	61
94	The Influence of Postweaning Housing Conditions on Drug-Induced Conditioned Taste Aversion. Pharmacology Biochemistry and Behavior, 1998, 59, 379-386.	2.9	20
95	An Investigation Into the Effects of 5-HT Agonists and Receptor Antagonists on Ethanol Self-Administration in the Rat. Alcohol, 1998, 16, 249-270.	1.7	37
96	Bidirectional Effects of Dopamine D2 Receptor Antagonists on Responding for a Conditioned Reinforcer. Pharmacology Biochemistry and Behavior, 1997, 57, 843-849.	2.9	22
97	Post-weaning housing conditions influence the behavioural effects of cocaine and d -amphetamine. Psychopharmacology, 1997, 131, 23-33.	3.1	106
98	The 5-HT1A receptor agonist 8-OH-DPAT reduces ethanol intake and maintained behavior in female Sprague-Dawley rats. Alcohol, 1996, 13, 407-413.	1.7	23
99	Initiation and maintenance of oral ethanol self-administration in female Sprague-Dawley rats. Alcohol, 1994, 11, 207-218.	1.7	18
100	The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiology and Behavior, 1993, 54, 689-693.	2.1	69
101	Feeding pattern studies suggest that d-fenfluramine and sertraline specifically enhance the state of satiety in rats. European Journal of Pharmacology, 1992, 211, 137-142.	3.5	19
102	Role of 5-HT receptors in the effect of d-fenfiuramine on gastric emptying and feeding behaviour as examined in the runway test. European Journal of Pharmacology, 1991, 197, 69-73.	3.5	8
103	Exposure to the calls of predators of mice activates defensive mechanisms and inhibits consummatory behaviour in an inbred mouse strain. Neuroscience and Biobehavioral Reviews, 1991, 15, 479-482.	6.1	24
104	Studies on the role of 5-HT receptors in satiation and the effect of d-fenfluramine in the runway test. European Journal of Pharmacology, 1990, 190, 105-112.	3.5	16
105	Evidence that d-fenfluramine anorexia is mediated by 5-HT1 receptors. Psychopharmacology, 1989, 97, 213-218.	3.1	122
106	Selective reduction by serotonergic agents of hypertonic saline consumption in rats: evidence for possible 5-HT1C receptor mediation. Psychopharmacology, 1989, 99, 196-201.	3.1	30
107	Central and Peripheral 5-HT Receptors Mediate Reductions in Sucrose Sham Feeding in the Rat. Annals of the New York Academy of Sciences, 1989, 575, 606-608.	3.8	1
108	Effects of 5-hydroxytryptamine and d-fenfluramine on sham feeding and sham drinking in the gastric-fistulated rat. Physiology and Behavior, 1989, 46, 949-953.	2.1	16

#	Article	IF	CITATIONS
109	MDL 72832, a selective 5-HT1A receptor ligand, stereospecifically increases food intake. European Journal of Pharmacology, 1988, 151, 329-332.	3.5	25
110	Specific effect of putative 5-HT1A agonists, 8-OH-DPAT and gepirone, to increase hypertonic saline consumption in the rat: Evidence against a general hyperdipsic action. Physiology and Behavior, 1988, 43, 533-537.	2.1	22
111	Evidence for serotonergic modulation of sucrose sham-feeding in the gastric-fistulated rat. Physiology and Behavior, 1988, 44, 453-459.	2.1	25
112	5-H Treceptors and the sweet tooth. Trends in Pharmacological Sciences, 1987, 8, 199-200.	8.7	5
113	Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor. European Journal of Pharmacology, 1987, 133, 47-56.	3.5	103
114	Partial agonists acting at benzodiazepine receptors can be differentiated in tests of ingestional behaviour. Physiology and Behavior, 1987, 41, 247-255.	2.1	16
115	Pharmacological analysis of the behavioural and thermoregulatory effects of the putative 5-HT1 receptor agonist, RU 24969, in the rat. Neuropharmacology, 1986, 25, 877-886.	4.1	129